17,261 trials
Chagas Disease
Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants
Bacterial Infections
Primary: MS Counts of Stimulated Saliva — 4.86; 4.40; 4.29; 3.78 MS counts log CFU/ml
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 12; 10; 81; 63 Percentages of subjects
Carcinoma, Squamous Cell
Primary: Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT — -21 percentage of change
Malignant Melanoma
Primary: Percentage of Participants With Adverse Events (AEs) — 96; 83; 92; 17 percentage of participants
Glioblastoma Multiforme
Primary: Percentage of Participants Alive 6 Months After Start of Treatment — 62.07; 73.33 percentage of participants — p=0.4291
Stroke
Primary: Feasibility of Recruitment Process — 120; 49; 20; 12 participants
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Carcinoma, Hepatocellular
Primary: Maximum Tolerated Dose in Phase I — 200; 200 mg bid
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Allergic Conjunctivitis
Primary: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)] at Day 7 — -2.8; -4.7; -8.1; -4.5 hours x units on a scale
End Stage Renal Disease (ESRD)
Primary: Number of Participants With Serious Infectious Complications Following Transplantation — 2 participants
Recurrent Endometrial Carcinoma
Primary: Tumor Response — 24.5 percentage of participants
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants